한빛사논문
- 조회452
Kim, Dongwoo MD∗; Yi, Ju Hyeon†; Park, Youngjoo†; Kim, Sun Jung MD‡; Kang, Seok-Gu MD, PhD§; Kim, Se Hoon MD, PhD∥; Chun, Joong-Hyun PhD∗; Chang, Jong Hee MD, PhD§; Yun, Mijin MD, PhD∗
From the ∗Department of Nuclear Medicine, Severance Hospital, Yonsei University College of Medicine
†Yonsei University College of Medicine, Seoul
‡Department of Nuclear Medicine, National Health Insurance Service Ilsan Hospital, Goyang
Departments of §Neurosurgery
∥Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
D.K. and J.H.Y. contributed equally to this work.
Correspondence to: Mijin Yun, MD, PhD, or Jong Hee Chang, MD, PhD
Abstract
Purpose: 11C-acetate (ACE) PET/CT visualizes reactive astrogliosis in tumor microenvironment. This study compared 11C-ACE and 11C-methionine (MET) PET/CT for glioma classification and predicting patient survival.
Patients and methods: In this prospective study, a total of 142 patients with cerebral gliomas underwent preoperative MRI, 11C-MET PET/CT, and 11C-ACE PET/CT. Tumor-to-contralateral cortex (TNRMET) and tumor-to-choroid plexus ratios (TNRACE) were calculated for 11C-MET and 11C-ACE. The Kruskal-Wallis test and Bonferroni post hoc analysis were used to compare the differences in 11C-TNRMET and 11C-TNRACE. The Cox proportional hazards regression analysis and classification and regression tree models were used to assess progression-free survival (PFS) and overall survival (OS).
Results: The median 11C-TNRMET and 11C-TNRACE for oligodendrogliomas (ODs), IDH1-mutant astrocytomas, IDH1-wildtype astrocytomas, and glioblastomas were 2.75, 1.40, 2.30, and 3.70, respectively, and 1.40, 1.20, 1.77, and 2.87, respectively. The median 11C-TNRMET was significantly different among the groups, except between ODs and IDH1-wildtype astrocytomas, whereas the median 11C-TNRACE was significantly different among all groups. The classification and regression tree model identified 4 risk groups (IDH1-mutant with 11C-TNRACE ≤ 1.4, IDH1-mutant with 11C-TNRACE > 1.4, IDH1-wildtype with 11C-TNRACE ≤ 1.8, and IDH1-wildtype with 11C-TNRACE > 1.8), with median PFS of 52.7, 44.5, 25.9, and 8.9 months, respectively. Using a 11C-TNRACE cutoff of 1.4 for IDH1-mutant gliomas and a 11C-TNRACE cutoff of 2.0 for IDH1-wildtype gliomas, all gliomas were divided into 4 groups with median OS of 52.7, 46.8, 27.6, and 12.0 months, respectively. Significant differences in PFS and OS were observed among the 4 groups after correcting for multiple comparisons.
Conclusions: 11C-ACE PET/CT is better for glioma classification and survival prediction than 11C-MET PET/CT, highlighting its potential role in cerebral glioma patients.
논문정보
- Research article
- 2023년 12월 (BRIC 등록일 2023-12-06)
- 국내 연구진
- 의약학 > 응용의학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
